In recent years, one of the most discussed topics in the UK CBD market has been the change in recommended daily intake. What was once commonly understood to be around 70mg per day has now shifted to a more cautious guideline of approximately 10mg per day. For many consumers, this has raised important questions about what has changed and how it affects the way CBD products are used.
While this adjustment may appear significant, it is best understood as part of a broader shift within the CBD industry. As regulation becomes more structured and the market continues to develop, guidance is evolving alongside it. Rather than signalling a problem, this change reflects a move towards greater consistency, clarity, and long-term stability.
Understanding the Change in Guidance
The earlier guidance of around 70mg per day emerged during a time when the CBD market was still developing and formal regulation was limited. Products varied widely in strength, formulation, and quality, and there was little standardisation across the industry.
As CBD use became more widespread, regulators began to take a closer look at how products were being sold and used. This led to the introduction of more structured guidance, including a revised recommendation of around 10mg per day.
This updated figure is based on a more cautious and standardised approach, designed to provide a clear reference point for consumers while the industry continues to evolve. It does not mean that CBD itself has fundamentally changed, but rather that guidance is becoming more refined as part of a maturing market.
Why a More Cautious Approach Has Been Introduced
The shift towards a lower daily guideline reflects a broader trend in how emerging industries are regulated. In the early stages of any new market, products often develop more quickly than the frameworks designed to oversee them.
As time goes on, regulators aim to introduce clearer structures that ensure consistency and safety across the board. In the case of CBD, this has led to a more measured approach to recommended intake, allowing for a standard reference point while further research and data continue to develop.
This cautious approach also helps create a more uniform understanding of CBD products across the market. By providing a consistent guideline, regulators can reduce confusion and encourage clearer communication between brands and consumers.
What This Means in Practice
For consumers, the introduction of a 10mg guideline is best seen as a reference rather than a strict limit. It provides a baseline that helps standardise how CBD products are discussed and labelled, making it easier to compare different options.
At the same time, it is important to recognise that CBD products still vary widely in strength and formulation. Oils, capsules, edibles, and topical products can all deliver different experiences depending on how they are used.
This means that understanding product strength, serving size, and intended use remains just as important as ever. Rather than focusing solely on a single number, consumers benefit from looking at the overall quality and consistency of the product they are choosing.
The Role of Regulation in Shaping the Market
The updated guidance is part of a wider effort to bring structure to the UK CBD industry. Alongside the Novel Foods process, it represents a move towards clearer standards and improved transparency.
As these frameworks develop, they are helping to create a more reliable marketplace. Products that meet regulatory expectations are more likely to offer consistent quality, accurate labelling, and greater overall trust.
While this process is still ongoing, it is already having a noticeable impact. The market is becoming more professional, with a stronger emphasis on testing, compliance, and long-term credibility.
Why the Change Has Created Confusion
Despite the benefits of increased structure, the shift from around 70mg to 10mg has understandably caused confusion among consumers. Many people who have used CBD for years are now seeing a recommendation that differs significantly from what they were previously familiar with.
This highlights one of the key challenges of a developing industry: guidance can change as understanding improves. What was once considered standard may be refined over time as more information becomes available and regulatory frameworks become more established.
In this context, the change is not a contradiction but a sign of progress. It reflects a move towards clearer, more consistent standards that can support long-term growth.
Choosing the Right CBD Products
As guidance evolves, the importance of choosing high-quality CBD products becomes even more significant. With more structure in the market, consumers are in a better position to identify products that meet consistent standards.
This includes looking for products that are lab tested, clearly labelled, and produced by established brands with a focus on quality and compliance. These factors provide reassurance in a market that is still developing and help ensure a more consistent experience.
For those exploring different strengths and formulations, selecting a trusted source of CBD Oil UK products offers a reliable starting point, combining quality control with clear product information.
A More Structured Future
The introduction of the 10mg guideline is just one example of how the UK CBD market is becoming more defined. While changes like this can initially create uncertainty, they ultimately contribute to a stronger and more reliable industry.
As regulation continues to evolve, consumers can expect to see further improvements in product consistency, transparency, and overall standards. Over time, this will make it easier to navigate the market and choose products with confidence.
Rather than viewing the change in guidance as a limitation, it can be seen as part of the natural progression of a growing industry. The UK CBD market is moving towards greater clarity, and with that comes a more stable and trustworthy environment for both businesses and consumers.
